Terminated PHASE3 INTERVENTIONAL 2-arm NCT01696643

Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions Opioid-Induced Constipation

Interventions CB-5945 Placebo

Updated 13 times since 2017 Last updated: Oct 17, 2018 Started: Oct 12, 2012 Primary completion: Jul 21, 2014 Completion: Jul 21, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met

Other terminated trials from Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

See all terminations from Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Other Opioid-Induced Constipation trials with similar outcome

Browse all Opioid-Induced Constipation trials

Listed as NCT01696643, this PHASE3 trial focuses on Opioid-Induced Constipation and remains terminated or withdrawn. Sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), it has been updated 13 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2024 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jan 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 8 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Dec 2018 — Nov 2020 [monthly]

Terminated PHASE3
Sep 2018 — Dec 2018 [monthly]

Terminated PHASE3
Jun 2018 — Sep 2018 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Data source: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.